Abstract:Abstract Background Alzheimer’s disease (AD) mutations in amyloid precursor protein ( APP ) and presenilins ( PSENs ) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ 1–43 is more prone to aggregation and has higher toxic properties than the long-known Aβ 1–42 . However, a direct effect on Aβ 1–43 in biomaterials of individuals carrying genetic mutations in the known AD genes is yet to be determined. Methods N = 1431 AD patients ( n = 280 early-onset (EO) and n = 1151 late-onset (LO) AD) and 809 control individuals were genetically screened for APP and PSENs . For the first time, Aβ 1–43 levels were analysed in cerebrospinal fluid (CSF) of 38 individuals carrying pathogenic or unclear rare mutations or the common PSEN1 p.E318G variant and compared with Aβ 1–42 and Aβ 1–40 CSF levels. The soluble sAPPα and sAPPβ species were also measured for the first time in mutation carriers. Results A known pathogenic mutation was identified in 5.7% of EOAD patients (4.6% PSEN1 , 1.07% APP ) and in 0.3% of LOAD patients. Furthermore, 12 known variants with unclear pathogenicity and 11 novel were identified. Pathogenic and unclear mutation carriers showed a significant reduction in CSF Aβ 1–43 levels compared to controls ( p = 0.037; < 0.001). CSF Aβ 1–43 levels positively correlated with CSF Aβ 1–42 in both pathogenic and unclear carriers and controls (all p < 0.001). The p.E318G carriers showed reduced Aβ 1–43 levels ( p < 0.001), though genetic association with AD was not detected. sAPPα and sAPPβ CSF levels were significantly reduced in the group of unclear ( p = 0.006; 0.005) and p.E318G carriers ( p = 0.004; 0.039), suggesting their possible involvement in AD. Finally, using Aβ 1–43 and Aβ 1–42 levels, we could re-classify as “likely pathogenic” 3 of the unclear mutations. Conclusion This is the first time that Aβ 1–43 levels were analysed in CSF of AD patients with genetic mutations in the AD causal genes. The observed reduction of Aβ 1–43 in APP and PSENs carriers highlights the pathogenic role of longer Aβ peptides in AD pathogenesis. Alterations in Aβ 1–43 could prove useful in understanding the pathogenicity of unclear APP and PSENs variants, a critical step towards a more efficient genetic counselling.

Nonfibrillar Diffuse Amyloid Deposition Due To A Gamma(42)-Secretase Site Mutation Points To An Essential Role For N-Truncated A Beta(42) In Alzheimer'S Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production

APP Substitutions V715F and L720P Alter PS1 Conformation and Differentially Affect Abeta and AICD Generation.

Intraneuronal Abeta42 accumulation in human brain.

Construction of Drug Screening Cell Model and Application to New Compounds Interfering Production and Accumulation of Beta-Amyloid by Inhibiting Gamma-Secretase

S4-03-01: Evidence That Aberrant Post-Tgn Trafficking of Alzheimer’s APP is Sufficient to Elevate Brain A-beta 42 and May Underlie Mutant Presenilin Action

Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis.

Mechanism of the Cleavage Specificity of Alzheimer'S Disease Gamma-Secretase Identified by Phenylalanine-Scanning Mutagenesis of the Transmembrane Domain of the Amyloid Precursor Protein

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

Mutations in APP have independent effects on Abeta and CTFgamma generation.

Intraneuronal Alzheimer A Beta 42 Accumulates in Multivesicular Bodies and is Associated with Synaptic Pathology

Alzheimer’s disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling

Endoplasmic Reticulum and Trans-Golgi Network Generate Distinct Populations of Alzheimer Beta-Amyloid Peptides

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

Alzheimer's disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling

Advances in the β-amyloid precursor protein of Alzheimer's disease

Proteolysis of Chimeric β-Amyloid Precursor Proteins Containing the Notch Transmembrane Domain Yields Amyloid β-like Peptides

The Gamma-Secretase Complex: from Structure to Function

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Longer Forms of Amyloid Β Protein: Implications for the Mechanism of Intramembrane Cleavage by Γ-Secretase